- Home
- LFCR vs ANL Comparison
LFCR vs ANL Comparison
Compare LFCR & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | LFCR | ANL |
|---|---|---|
| Founded | 1986 | 2004 |
| Country | United States | Cayman Islands |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 269.8M | 293.4M |
| IPO Year | 1996 | 2022 |
Fundamental Metrics
Financial Performance| Metric | LFCR | ANL |
|---|---|---|
| Price | $4.15 | $7.76 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | $5.50 | ★ $16.00 |
| AVG Volume (30 Days) | ★ 279.4K | 205.2K |
| Earning Date | 03-16-2026 | 04-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $557,559,000.00 | N/A |
| Revenue This Year | $2.32 | N/A |
| Revenue Next Year | $11.51 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 6.36 | N/A |
| 52 Week Low | $4.09 | $0.88 |
| 52 Week High | $8.98 | $12.09 |
Technical Indicators
Market Signals| Indicator | LFCR | ANL |
|---|---|---|
| Relative Strength Index (RSI) | 9.73 | 45.10 |
| Support Level | N/A | $7.21 |
| Resistance Level | $8.54 | $9.98 |
| Average True Range (ATR) | 0.50 | 0.97 |
| MACD | -0.30 | -0.30 |
| Stochastic Oscillator | 0.92 | 20.85 |
Price Performance
Historical ComparisonAbout LFCR Lifecore Biomedical Inc.
Lifecore Biomedical Inc is a fully integrated contract development and manufacturing organization (CDMO) that provides services in the development, fill, and finish of complex sterile injectable pharmaceutical products in syringes, vials, and cartridges. The group recognizes revenue in two different product categories, CDMO and HA manufacturing.
About ANL Adlai Nortye Ltd.
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.